Navigation Links
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Date:5/22/2008

- Lead Candidate, RDEA806, Demonstrated No Reproductive Toxicity in

Preclinical Study - - RDEA427 Selected as Clinical Candidate, Demonstrated a 40 Hour Half-Life

with Potential for Once Daily Oral Dosing -

SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor (NNRTI) candidate, RDEA806, demonstrating no reproductive toxicity. In addition, novel second-generation NNRTI, RDEA427, was selected as a development candidate for the potential treatment of the human-immunodeficiency virus (HIV), the causative agent of AIDS.

Animal reproductive toxicity studies recently completed with RDEA806 have demonstrated no effects on male or female fertility or on early embryonic development at all tested doses. These results are in contrast to the fetal malformations reported in other NNRTI animal reproductive toxicity studies.

Exploratory human testing (Phase 0) of RDEA427 was recently completed in which micro-doses of the compound were administered to healthy volunteers. Preliminary pharmacokinetic data from this study, produced by Vitalea Science, Inc. using Accelerator Mass Spectrometry (AMS) technology, demonstrated that RDEA427 has a half-life of approximately 40 hours, which could permit once daily oral dosing.

"The ability to use RDEA806 in women, without the risk of birth defects, is a major advantage over the current first-line NNRTI. Women make up 26% of HIV/AIDS diagnosed patients in the United States, and an even larger percent of infected patients worldwide. These preclinical data for RDEA806 further strengthen its impressive product profile," said
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
2. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... colored ribbon representing a disease. A pink ribbon is well ... one think of with lung cancer?, Although white has been ... disease, black may be the only one they think fits., ... primarily smokers between the ages of 51 to 79 years ... by these patients, the emotional toll it can have and ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... $25 million project to reduce throughout the beef production chain ... a major threat to public health. The U.S. Department ... grant at UNL on Monday, Jan. 23. The project ... cause more than 265,000 illnesses in the United States annually. ...
... Higher than normal levels of lead in the blood may ... renal cell carcinoma in smokers, according to medical researchers. ... kidneys from individuals without cancer, kidneys from individuals with cancer ... at Penn State College of Medicine. "But prior to this ...
... HealthDay Reporter , SUNDAY, Jan. 22 (HealthDay ... they believe are linked with breast cancer that may ... All three newly identified areas "contain interesting genes that ... said researcher Douglas Easton, a professor of genetic epidemiology ...
... Angry Men," Henry Fonda,s character sways a jury with his ... had allowed himself to fall sway to the social dynamics ... Virginia Tech Carilion Research Institute found that small-group dynamics -- ... -- can alter the expression of IQ in some susceptible ...
... yoga in a room heated to between 90 and 105 degrees ... it may not be for everyone, an expert warns. Exertion ... conditions, said Diana Zotos, a yoga instructor and physical therapist ... New York City. "If you have sensitivity to ...
... -- Monkeys vaccinated with an anthrax capsule vaccine were protected ... The anthrax capsule is a naturally occurring component of ... is the first successful use of a non-toxin vaccine to ... the most serious bioterrorism threats, according to the U.S. Army ...
Cached Medicine News:Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 3Health News:Lead blood levels may increase smokers' risk for kidney cancer 2Health News:Lead blood levels may increase smokers' risk for kidney cancer 3Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Group settings can diminish expressions of intelligence, especially among women 2Health News:Group settings can diminish expressions of intelligence, especially among women 3Health News:Avoid Getting Scorched by 'Hot Yoga' 2Health News:Anthrax Vaccine Shows Promise in Monkeys 2
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Our largest silicone tire with concave inner surface. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Massive breaks covering large areas. Outside diameter 31.7 mm....
Medicine Products: